World Hepatitis Day: All You Need To Know About The Disease outlookindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outlookindia.com Daily Mail and Mail on Sunday newspapers.
Increased access to testing, treatment has reduced hepatitis C in low- and middle-income countries
Many low- and middle-income countries have reduced suffering from hepatitis C, thanks to increased access to testing and treatment. Some achieved a 20-fold increase in the number of people treated with safe and effective direct-acting retroviral drugs between 2015 and 2018, according to the
Global progress report on accelerating access to hepatitis C diagnostics and treatment, released by WHO today.
A drop in prices underpins this success
Low- and middle-income countries can now aim to achieve a price as low as US$ 60 per patient for a 12-week course of treatment with WHO-prequalified generic sofosbuvir and daclatasvir. Prices offered by suppliers of WHO-prequalified HCV rapid diagnostic tests ranged between US$ 1 and US$ 8 per test.
Accelerating access to hepatitis C diagnostics and treatment: Overcoming barriers in low- and middle-income countries - Global progress report 2020
Format
The 2020 global report on access to hepatitis C diagnostics and treatment is being published at
an unprecedented time for global health. The data presented in this report were collected in 2019. Since then, the coronavirus disease (COVID)-19 pandemic has spread to countries and populations worldwide, resulting in 79 million infections and about 1.7 million deaths by end December 2020. Many countries are already facing major disruptions to essential health services. They risk a reversal of decades of progress in health and development. The pandemic is a strong reminder that we need to continue to invest in building resilient health systems for universal health coverage and respond to emergencies. It is also an urgent call to maintain the momentum towards achieving the goals of the 2030 Agenda for Sustainable Development.
Date Time
WHO on progress in access to hepatitis C diagnostics and treatment
Many low- and middle-income countries have reduced suffering from hepatitis C, thanks to increased access to testing and treatment. Some achieved a 20-fold increase in the number of people treated with safe and effective direct-acting retroviral drugs between 2015 and 2018, according to the Global progress report on accelerating access to hepatitis C diagnostics and treatment, released by WHO today.
A drop in prices underpins this success
Low- and middle-income countries can now aim to achieve a price as low as US$ 60 per patient for a 12-week course of treatment with WHO-prequalified generic sofosbuvir and daclatasvir. Prices offered by suppliers of WHO-prequalified HCV rapid diagnostic tests ranged between US$ 1 and US$ 8 per test.